EUCTR2006-002787-26-DE进行中（未招募）1 期
A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab, Remicade®) in Combination with Methotrexate in Patients with Very Early Inflammatory Arthritis - DINORA
Department of Rheumatology, Medical University of Vienna0 个研究点目标入组 90 人开始时间: 2007年10月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Men and women, = 18 and = 75 years of age, capable of understanding and signing an informed consent.
- •2) The presence of arthritis:
- •a) Must be established in a rheumatology center,
- •b) Must be present in at least 2 joints of the 66 joint count, of which at least one joint must be an MCP-, or a PIP- (IP-) or a wrist- or a MTP-joint. Two MTP-joints will not suffice. Any kind of polyarthritis (= 6 joints of any kind) will be sufficient.
- •c) Without any previous episodes of inflammatory joint disease
- •3) Duration of symptoms :
- •a) Must be assessed by the subject and should involve the inflamed joints described under 2.
- •b) Must be 2 weeks at least, according to the algorithm in Table 1 (subjects will not receive study treatment before 12 weeks of symptom duration according to the algorithm in Table 1)
- •c) Must be 16 weeks at most, as assessed by the subject, including the observation period of at least 2 weeks by the physician, according to the algorithm in Table 1.
- •4) Confirmation of persistent arthritis:
- •a) Duration must be 2 weeks at least, according to the algorithm in Table 1.
- •b) Duration must be 12 weeks at most, according to the algorithm in Table 1.
- •c) Must be documented by the same rheumatology center that established arthritis at the first visit
- •d) Must involve at least one of the same joints as were involved at the first visit
- •5) Men and women of childbearing potential must use adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilization) for the duration of the study and should continue such precautions for 6 months after receiving the last medication.
- •6) Are considered eligible according to the tuberculosis (TB) eligibility assessment, screening, and early detection of reactivation rules defined in Section 7.14: Tuberculosis Eligibility Assessment, Screening, and Early Detection of Reactivation
- •7) Chest radiograph (which must not be older than three months at the visit 1/day 0 visit) must show no evidence of malignancy, infection, or fibrosis. The chest radiograph should also show no atypical scarring, cavitary lesions, or calcified granulomas, as evidence of past tuberculosis infections, without a documented history of adequate therapy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients must not
- •1) Have arthritis with a distinct diagnosis, made after a routine diagnostic work-up (examples are SLE, psoriatic arthritis, systemic sclerosis, gout, pseudogout, Lyme arthritis, reactive arthritis, Parvo viral arthritis)
- •2) Be incapacitated, largely or wholly bedridden, or confined to a wheelchair, or have little or no ability for self care.
- •3) Weigh more than 100 kg
- •4) Use glucocorticoids > 10 mg/day prednisone or equivalent
- •5) Have received Intramuscular or intra-articular injection of steroids in the previous month.
- •6) Have Screening laboratory test results as follows:
- •a)White blood cells (WBCs) < 3.0 x 109 cells/L
- •b)Platelets < 100 X 109 cells/L
- •c)Serum creatinine > 1.4 mg/dL
- •d)Serum transaminase levels exceeding 2 times the upper limit of normal for the site laboratory
- •7) Have had any previous treatment with monoclonal antibodies or antibody fragments.
- •8) Have a history of receiving human/murine recombinant products or a known allergy to murine products. A known allergy to murine product is definitely an exclusion criterion.
- •9) Have had prior treatment with MTX and/or other DMARDs (except hydroxychloroquine).
- •10) Have documentation of seropositivity for human immunodeficiency virus (HIV).
- •11) Have documentation of a positive test for hepatitis B surface antigen or hepatitis C-antibodies.
- •12) Have a history of alcohol or substance abuse within the preceding 6 months that, in the opinion of the investigator, may increase the risks associated with study participation or study agent administration, or may interfere with interpretation of results.
- •13) Have a known history of serious infections (such as, but not limited to hepatitis, pneumonia, or pyelonephritis) in the previous 3 months.
- •14) Have a known history of a demyelinating disease, such as multiple sclerosis
- •15) Have or have had an opportunistic infection (eg, herpes zoster [shingles], cytomegalovirus, Pneumocystis carinii, aspergillosis, histoplasmosis, or mycobacteria other than TB) within 12 months prior to screening.
- •16) Have undergone any joint replacement surgery.
- •17) Have a chronic or recurrent infectious disease, including but not limited to, chronic renal infection, chronic chest infection (eg. bronchiectasis), sinusitis, recurrent urinary tract infection, open, draining or infected skin wound or ulcer.
- •18) Be considered ineligible according to the TB eligibility assessment, screening, and early detection of reactivation rules defined in Section on: Tuberculosis Eligibility Assessment, Screening, and Early Detection of Reactivation Rules
- •19) Have a chest radiograph at screening that shows evidence of malignancy, infection, or any abnormalities suggestive of TB.
- •20) Have a history of lymphoproliferative disease, including lymphoma or signs suggestive of possible lymphoproliferative disease such as lymphadenopathy of unusual size or location (eg, nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic area), or splenomegaly.
- •21) Currently have any known malignancy other than the condition being treated or have a history of malignancy within the previous 5 years, with the exception of basal cell or squamous cell carcinoma of the skin that has been fully excised with no evidence of recurrence.
- •22) Have current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.
研究者
相似试验
招募中
3 期
Evaluate the Efficacy and Safety of Thymosin α-1 (Tα1) with comparision of placebo in sepsis patient by using with Standrad of careCTRI/2022/09/045538Gufic Biosciences Limited
进行中（未招募）
1 期
Study is to find out more about evolocumab in HIV-positive patient`s and with high cholesterol(hyperlipidemia and/or mixed dyslipidemia).HIV and hyperlipidemia or mixed dyslipidemiaMedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861MedDRA version: 23.0Level: LLTClassification code 10020667Term: HyperlipidemiaSystem Organ Class: 100000004861MedDRA version: 21.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861MedDRA version: 20.0Level: LLTClassification code 10020180Term: HIV positiveSystem Organ Class: 100000004848EUCTR2015-004735-12-ITAMGEN INC.467
进行中（未招募）
1 期
Study is to find out more about evolocumab in HIV-positive patient`s and with high cholesterol (hyperlipidemia and/or mixed dyslipidemia).HIV and hyperlipidemia or mixed dyslipidemia.MedDRA version: 21.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861MedDRA version: 23.0Level: LLTClassification code 10020667Term: HyperlipidemiaSystem Organ Class: 100000004861MedDRA version: 20.0Level: LLTClassification code 10020180Term: HIV positiveSystem Organ Class: 100000004848MedDRA version: 21.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2015-004735-12-PTAmgen Inc467
进行中（未招募）
1 期
Study is to find out more about evolocumab in HIV-positive patient`s and with high cholesterol (hyperlipidemia and/or mixed dyslipidemia).HIV and hyperlipidemia or mixed dyslipidemia.MedDRA version: 20.1Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861MedDRA version: 20.1Level: LLTClassification code 10020667Term: HyperlipidemiaSystem Organ Class: 100000004861MedDRA version: 20.0Level: LLTClassification code 10020180Term: HIV positiveSystem Organ Class: 100000004848MedDRA version: 20.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2015-004735-12-FRAmgen Inc450
进行中（未招募）
不适用
A Double Blind, Randomized, Placebo Controlled, Multi-Center Trial of Anti-TNFafa Chimeric Monoclonal Antibody (Infliximab, Remicade®) and Azathioprine in Patients Suffering from Systemic Lupus Erythematosus (SLE) with WHO Class V GlomerulonephritisSystemic Lupus Erythematosus (SLE) with WHO Class V GlomerulonephritisEUCTR2005-004067-30-ATDepartment of Rheumatology, Internal Medicine III, Medical University of Vienna44